Payment overview · 2025
General Payments
$151.80
7 reported records · 5 companies
Healthcare provider profile · identity verified
Jack Geffken, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BETHPAGE, NY · NPI 1053310268
Verified facts
What the public records show
CMS Open Payments records show Jack Geffken, D.O. received $151.80 in general payments during 2025 across 7 reported records.
Dexcom, Inc. accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.08 | 32.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.03 | 24.4% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $25.00 | 16.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.54 | 14.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.15 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.80 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.08 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 330 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 90 |
| Alprazolam | Alprazolam | 231 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 62 |
| Metformin Hcl Er | Metformin Hcl | 155 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 40 |
| Famotidine | Famotidine | 124 | 51 |
| Losartan Potassium | Losartan Potassium | 124 | 43 |
| Ezetimibe | Ezetimibe | 114 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 19 |
| Gabapentin | Gabapentin | 107 | 32 |
| Simvastatin | Simvastatin | 107 | 31 |
| Omeprazole | Omeprazole | 101 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 97 | 25 |
| Ozempic | Semaglutide | 97 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 22 |
| Furosemide | Furosemide | 84 | 35 |
| Synthroid | Levothyroxine Sodium | 84 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 25 |
| Sertraline Hcl | Sertraline Hcl | 79 | 22 |
| Meloxicam | Meloxicam | 78 | 34 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 77 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 76 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 30 |
| Januvia | Sitagliptin Phosphate | 75 | 21 |
| Valsartan | Valsartan | 75 | 24 |
| Donepezil Hcl | Donepezil Hcl | 71 | 21 |
| Eliquis | Apixaban | 70 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 20 |
| Bupropion Xl | Bupropion Hcl | 63 | 16 |
| Celecoxib | Celecoxib | 62 | 32 |
| Glimepiride | Glimepiride | 59 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 17 |
| Clonazepam | Clonazepam | 55 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 28 |
| Metformin Hcl | Metformin Hcl | 53 | 16 |
| Lisinopril | Lisinopril | 52 | 16 |
| Trazodone Hcl | Trazodone Hcl | 52 | 18 |
| Mirtazapine | Mirtazapine | 51 | 11 |
| Montelukast Sodium | Montelukast Sodium | 51 | 18 |
| Benazepril Hcl | Benazepril Hcl | 47 | 11 |
| Atenolol | Atenolol | 46 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 14 |
| Ramipril | Ramipril | 44 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 32 |
| Farxiga | Dapagliflozin Propanediol | 43 | 11 |
| Allopurinol | Allopurinol | 42 | 15 |
| Potassium Chloride | Potassium Chloride | 39 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Jardiance | Empagliflozin | 37 | 13 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Prednisone | Prednisone | 35 | 35 |
| Carvedilol | Carvedilol | 34 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 14 |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Testosterone | Testosterone | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Finasteride | Finasteride | 29 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 17 |
| Linzess | Linaclotide | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.80 · 7 records | Dexcom, Inc. | Dexcom G6 Transmitter, MOUNJARO, Ozempic, UNITHROID, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error